Market Overview:
Auto-injectors fall under an importantsegment of
medical devices designed to drug dose delivery in a calculated manner. These
injectors are used for delivering life-saving drugs. They are extremely
effective in tackling severe allergic reactions. Auto-injectors are one of the several
inventions focused toward bettering care giving. The continuous advances in
medical technology has led to development of effective auto-injectors. Latest
versions of the device are more user-friendly and cost-efficient. These
injectors are intended for self-administration by patients. They do not require
special training for homecare giversto administer drugs. Such factors make the
devices extremely important and practical. Market Research Future (MRFR)
projects that the global Auto-Injectors
Market will reach a valuation of more than USD 2 Bn by the year 2022. To
reach this valuation, the market is projected to exhibit a compound annual
growth rate (CAGR) of 17.2% from 2016 to 2022.
Get a Free Sample @ https://www.marketresearchfuture.com/sample_request/2046
The advent of auto-injectors has helped in tackling
the challenges faced in self-administration. These injectors are far more
superior than conventional needle-based drug delivery devices. The technology
is quite simple, as spring-loaded system is used in for functionality. Most
auto-injectors that are currently available have plastic body, which help in
deterring unnecessary contamination. Rising
incidences of allergic diseases associated with anaphylaxis and other allergies
globally is expected to influence the global auto-injectors market.
Global Auto-Injectors
Market:Competitive Landscape:
UNILIFE
CORPORATION, Enbrel, Owen Mumford Ltd., Amedra Pharmaceuticals LLC,
Scandinavian Health Ltd., and kaleo, Inc. are among the global auto-injectors
market.
Global
Auto-Injectors Market: Segmental Overview:
·
The segmental analysis of the global auto-injectors
market has been conducted on the basis ofproduct type, application, and
suppliers.
·
Based on product type, the market has been
segmented into reusable, disposable and others.
·
Based on application, the market has been segmented
into rheumatoid arthritis, anaphylaxis, multiple sclerosis, allergies and
others.
·
Based on supplier, the market has been segmented
into retailers, pharmacy, online retailers and others.
GlobalAuto-Injectors
Market: Regional Segmentation
Key regions mentioned in MRFR’s report include South America, North
America, Europe, Asia Pacific (APAC) and the Middle East & Africa (MEA). In
terms of revenue, North America holds the top spot in the global auto-injectors
market. In addition, the auto-injectors market in North America is projected to
reach the size of USD 0.9 Bn towards the end of assessment period. Faster
uptake of advanced technologies and presence of a robust healthcare systems in
the U.S. is supporting the market growth in the region. North America is
expected to remain a highly attractive market for auto-injectors during the
forecast period. Europe holds the second spot in the global auto-injectors
market in terms of revenue. Factors such as highhealthcare expenditure and strong
government support are propelling the market in Europe. Meanwhile, the APAC
auto-injectors market is expected to exhibit a register the highest CAGR during
the forecast period.
Industry
News
·
Lupin Limited, a multi-national pharmaceutical
company is reportedly positioning itself to enter the sterile injectable
products segment in distinct class of ready-to-use platform. The company has
significant capacity in both the supply chain and operation. The company
recently commissioned an injectables facility at Nagpur. The company has 9
R&D and 18 manufacturing units worldwide. Additionally, the company has a
vast product portfolio, which includes capsules, injectable, dry
powder inhalers (DPIs), tablets, metered dose inhalers (MDIs) and sterile
and non-sterile liquids.
·
US-based pharmaceutical company ARS
Pharmaceuticals, Inc., which specializes in assisting at-risk patients recently
announced the result from its EPI-04 clinical research analysis, which
evaluates the pharmacokinetics of epinephrine after administration of ARS-1. The
company is renowned for its offerings in severe allergic reactions.
No comments:
Post a Comment